Baidu
map

索他洛尔抗心律失常中国专家共识

2019-08-20 中国生物医学工程学会心律学分会 中国循环杂志.2019,34(8):741-751.

索他洛尔是一个兼有Ⅱ类和Ⅲ 类抗心律失常作用的药物,由于其长期用药的安全性良好,可一线用于预防心房颤动(左心室功能正常且无结构性心脏病,或伴有冠心病、瓣膜心脏病和左心室肥厚的心房颤动患者)复发;对于室性心律失常、房性早搏、房性心动过速也有较好疗效,也可用于植入型心律转复除颤器(ICD)术后的长期辅助治疗。索他洛尔口服剂量由40~80 mg bid 起始,逐步加量至160 mg bid;在用药最初3

中文标题:

索他洛尔抗心律失常中国专家共识

发布日期:

2019-08-20

简要介绍:

索他洛尔是一个兼有Ⅱ类和Ⅲ 类抗心律失常作用的药物,由于其长期用药的安全性良好,可一线用于预防心房颤动(左心室功能正常且无结构性心脏病,或伴有冠心病、瓣膜心脏病和左心室肥厚的心房颤动患者)复发;对于室性心律失常、房性早搏、房性心动过速也有较好疗效,也可用于植入型心律转复除颤器(ICD)术后的长期辅助治疗。索他洛尔口服剂量由40~80 mg bid 起始,逐步加量至160 mg bid;在用药最初3 d,监测QT 间期。索他洛尔是一种较有效的抗心律失常药物,值得中国医师关注。

 

拓展指南:心律失常相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=索他洛尔抗心律失常中国专家共识)] GetToolGuiderByIdResponse(projectId=1, id=0ca671c001e8a337, title=索他洛尔抗心律失常中国专家共识, enTitle=, guiderFrom=中国循环杂志.2019,34(8):741-751., authorId=null, author=, summary=索他洛尔是一个兼有Ⅱ类和Ⅲ 类抗心律失常作用的药物,由于其长期用药的安全性良好,可一线用于预防心房颤动(左心室功能正常且无结构性心脏病,或伴有冠心病、瓣膜心脏病和左心室肥厚的心房颤动患者)复发;对于室性心律失常、房性早搏、房性心动过速也有较好疗效,也可用于植入型心律转复除颤器(ICD)术后的长期辅助治疗。索他洛尔口服剂量由40~80 mg bid 起始,逐步加量至160 mg bid;在用药最初3, cover=, journalId=null, articlesId=null, associationId=438, associationName=中国生物医学工程学会心律学分会, associationIntro=先后共成立了工程学组、电生理学组、起搏学组、儿科学组、药理学组、地市培训学组等六个学组。 每两年举办一届中国心脏起搏与电生理学术年会,至今已举办十四届(中国心律学论坛)。并出版了《中国心律学》(人卫出版) 2008,2009和2010三本系列专著。 2001年成功地举办了四年一次的第七届亚太心脏起搏与电生理大会。会议有53个国家和地区 380名外宾和1200名国内专家和代表参加。368篇文摘刊登在美国《PACE》专业杂志,并出版了会议专集,另外有357篇刊登在国内印制的会议论文汇编上。 2002年全国近40个心律失常专家在京召开了&ldquo;射频消融治疗快速心律失常指南修改&rdquo;会议。 全国射频消融治疗快速心律失常注册: 自1996年中国生物医学工程学会心脏起搏与电生理分会首次在全国注册射频消融治疗快速心律失常资料以来,每年坚持完成注册登记工作。 &ldquo;离子通道病全国注册协作&rdquo;研究: 长QT综合征全国协作小组于 1999年成立为进一步促进国内的研究,了解研究动态,实现资源共享,将注册的病种扩大到全部的离子通道病,成立了离子通道病全国注册及国际协作研究小组,并邀请国际上该领域的知名专家共同进行中国的离子通道病研究。 自2010年学会牵头开展了&ldquo;J综合征注册研究&rdquo;和&ldquo;校园猝死高危人群筛查和防治&rdquo;, copyright=0, guiderPublishedTime=Tue Aug 20 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>索他洛尔是一个兼有Ⅱ类和Ⅲ 类抗心律失常作用的药物,由于其长期用药的安全性良好,可一线用于预防心房颤动(左心室功能正常且无结构性心脏病,或伴有冠心病、瓣膜心脏病和左心室肥厚的心房颤动患者)复发;对于室性心律失常、房性早搏、房性心动过速也有较好疗效,也可用于植入型心律转复除颤器(ICD)术后的长期辅助治疗。索他洛尔口服剂量由40~80 mg bid 起始,逐步加量至160 mg bid;在用药最初3 d,监测QT 间期。索他洛尔是一种较有效的抗心律失常药物,值得中国医师关注。 </P> <P> </P>拓展指南:<strong>与<font color=red>心律失常</font>相关指南:</strong><br><ul><li><a href="//www.sandwebs.com/guideline/show_article.do?id=31a891c001e7562d" title="2019 EHRA共识:急性冠脉综合征和血运重建紧急情况下的心律失常" target=_blank>2019 EHRA共识:急性冠脉综合征和血运重建紧急情况下的心律失常</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=41a2a1c001e71220" title="2019 HRS/EHRA/APHRS/LAHR专家共识声明:导管消融治疗室性心律失常" target=_blank>2019 HRS/EHRA/APHRS/LAHR专家共识声明:导管消融治疗室性心律失常</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=2a6951c001e7075f" title="2019 HRS/EHRA/APHRS/LAHR专家共识声明:导管消融治疗室性心律失常" target=_blank>2019 HRS/EHRA/APHRS/LAHR专家共识声明:导管消融治疗室性心律失常</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=06cf11c001ea02f6" title="2019 AHA科学声明:接受左心室辅助装置患者的设备治疗和心律失常的管理" target=_blank>2019 AHA科学声明:接受左心室辅助装置患者的设备治疗和心律失常的管理</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=c12e21c001e213f5" title="2019 EHRA共识:无症状心律失常的管理" target=_blank>2019 EHRA共识:无症状心律失常的管理</a></li> 更多信息请点击:<a href="//www.sandwebs.com/guideline/list.do?q=%E5%BF%83%E5%BE%8B%E5%A4%B1%E5%B8%B8" target=_blank>有关心律失常更多指南</a></ul>, tagList=[TagDto(tagId=12044, tagName=索他洛尔), TagDto(tagId=93676, tagName=心律失常v)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=21327, appHits=528, showAppHits=0, pcHits=19040, showPcHits=2859, likes=101, shares=14, comments=10, approvalStatus=1, publishedTime=Mon Aug 26 00:39:27 CST 2019, publishedTimeString=2019-08-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 26 00:39:27 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 15:58:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=索他洛尔抗心律失常中国专家共识)])
索他洛尔抗心律失常中国专家共识
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1084938, encodeId=75e810849381f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5442401149, createdName=12354be1m20暂无昵称, createdTime=Mon Dec 27 23:21:17 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962581, encodeId=1e309625817c, content=内容对自己帮助很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211231/4ee68eda74d2489a9f64709ec00bb253/7e5380d79dc449f59e42efcdab4134d3.jpg, createdBy=d9945307708, createdName=1487e204m23暂无昵称, createdTime=Tue May 04 09:22:14 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882136, encodeId=92bb88213657, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Wed Sep 02 10:11:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807735, encodeId=35bb80e73518, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:32 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807734, encodeId=d01380e73455, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:29 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2021-12-27 12354be1m20暂无昵称

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1084938, encodeId=75e810849381f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5442401149, createdName=12354be1m20暂无昵称, createdTime=Mon Dec 27 23:21:17 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962581, encodeId=1e309625817c, content=内容对自己帮助很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211231/4ee68eda74d2489a9f64709ec00bb253/7e5380d79dc449f59e42efcdab4134d3.jpg, createdBy=d9945307708, createdName=1487e204m23暂无昵称, createdTime=Tue May 04 09:22:14 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882136, encodeId=92bb88213657, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Wed Sep 02 10:11:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807735, encodeId=35bb80e73518, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:32 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807734, encodeId=d01380e73455, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:29 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2021-05-04 1487e204m23暂无昵称

    内容对自己帮助很多

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1084938, encodeId=75e810849381f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5442401149, createdName=12354be1m20暂无昵称, createdTime=Mon Dec 27 23:21:17 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962581, encodeId=1e309625817c, content=内容对自己帮助很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211231/4ee68eda74d2489a9f64709ec00bb253/7e5380d79dc449f59e42efcdab4134d3.jpg, createdBy=d9945307708, createdName=1487e204m23暂无昵称, createdTime=Tue May 04 09:22:14 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882136, encodeId=92bb88213657, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Wed Sep 02 10:11:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807735, encodeId=35bb80e73518, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:32 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807734, encodeId=d01380e73455, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:29 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-09-02 长毛小米

    好资料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1084938, encodeId=75e810849381f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5442401149, createdName=12354be1m20暂无昵称, createdTime=Mon Dec 27 23:21:17 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962581, encodeId=1e309625817c, content=内容对自己帮助很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211231/4ee68eda74d2489a9f64709ec00bb253/7e5380d79dc449f59e42efcdab4134d3.jpg, createdBy=d9945307708, createdName=1487e204m23暂无昵称, createdTime=Tue May 04 09:22:14 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882136, encodeId=92bb88213657, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Wed Sep 02 10:11:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807735, encodeId=35bb80e73518, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:32 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807734, encodeId=d01380e73455, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:29 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1084938, encodeId=75e810849381f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5442401149, createdName=12354be1m20暂无昵称, createdTime=Mon Dec 27 23:21:17 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962581, encodeId=1e309625817c, content=内容对自己帮助很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211231/4ee68eda74d2489a9f64709ec00bb253/7e5380d79dc449f59e42efcdab4134d3.jpg, createdBy=d9945307708, createdName=1487e204m23暂无昵称, createdTime=Tue May 04 09:22:14 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882136, encodeId=92bb88213657, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Wed Sep 02 10:11:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807735, encodeId=35bb80e73518, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:32 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807734, encodeId=d01380e73455, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:46:29 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

Baidu
map
Baidu
map
Baidu
map